Atrinsic (NASDAQ:PTIX) Shares Down 11.6% – Time to Sell?

Atrinsic Inc. (NASDAQ:PTIXGet Free Report) shares dropped 11.6% during mid-day trading on Tuesday . The stock traded as low as $0.4323 and last traded at $0.5460. Approximately 6,421 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 38,703 shares. The stock had previously closed at $0.6175.

Atrinsic Stock Down 11.6%

The company has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.90. The stock has a market capitalization of $988,260.00, a price-to-earnings ratio of -0.07 and a beta of 1.13.

About Atrinsic

(Get Free Report)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.

Further Reading

Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.